➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Medtronic
Harvard Business School
Dow
McKinsey

Last Updated: June 14, 2021

DrugPatentWatch Database Preview

TOFRANIL-PM Drug Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Tofranil-pm, and when can generic versions of Tofranil-pm launch?

Tofranil-pm is a drug marketed by Specgx Llc and is included in one NDA.

The generic ingredient in TOFRANIL-PM is imipramine pamoate. There are thirty-four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the imipramine pamoate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Tofranil-pm

A generic version of TOFRANIL-PM was approved as imipramine pamoate by HIKMA on April 16th, 2010.

  Get Started Free

Summary for TOFRANIL-PM
Drug patent expirations by year for TOFRANIL-PM
Recent Clinical Trials for TOFRANIL-PM

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Central Michigan UniversityN/A
Sheppard Pratt Health SystemN/A
Astellas Pharma IncN/A

See all TOFRANIL-PM clinical trials

US Patents and Regulatory Information for TOFRANIL-PM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Specgx Llc TOFRANIL-PM imipramine pamoate CAPSULE;ORAL 017090-001 Approved Prior to Jan 1, 1982 DISCN Yes No   Get Started Free   Get Started Free   Get Started Free
Specgx Llc TOFRANIL-PM imipramine pamoate CAPSULE;ORAL 017090-002 Approved Prior to Jan 1, 1982 DISCN Yes No   Get Started Free   Get Started Free   Get Started Free
Specgx Llc TOFRANIL-PM imipramine pamoate CAPSULE;ORAL 017090-004 Approved Prior to Jan 1, 1982 DISCN Yes No   Get Started Free   Get Started Free   Get Started Free
Specgx Llc TOFRANIL-PM imipramine pamoate CAPSULE;ORAL 017090-003 Approved Prior to Jan 1, 1982 DISCN Yes No   Get Started Free   Get Started Free   Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Baxter
McKesson
Johnson and Johnson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.